Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KL-A167 injection long-term safety in lymphoma
CTR20192416Phase 2Completed
- Sponsor
- Kelun-Biotech
- Start
- Dec 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tagitanlimab in lymphoma, sponsored by Kelun-Biotech. Started Dec 2019; status: completed.
02
Drugs
tagitanlimab
03
Conditions
lymphoma
Beyond the preview
Go deeper on CTR20192416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192416.